Navigation Links
Standard & Poor's Announces Changes to U.S. Indices
Date:11/11/2008

NEW YORK, Nov. 11 /PRNewswire/ --Standard & Poor's will make the following changes to the S&P 500 and S&P MidCap 400 indices:

-- General Growth Properties Inc. (NYSE Arca: GGP) will be removed from the

S&P 500 after the close of trading on Wednesday, November 12. As of

today's close of trading General Growth Properties had a market

value of approximately $128 million, ranking 500th in the index.

-- S&P MidCap 400 constituent Cephalon Inc. (Nasdaq: CEPH) will be

added to the S&P 500, and Mariner Energy Inc. (NYSE: ME) will

replace Cephalon Inc. in the S&P MidCap 400, after the close of

trading on Friday, November 14. Cephalon is taking the place of

General Growth Properties in the S&P 500.

Standard & Poor's will monitor these transactions, and post any relevant updates on its website: http://www.standardandpoors.com.

Cephalon is a biopharmaceutical developer specializing in products related to the central nervous system, pain, oncology and addiction. Headquartered in Frazer, PA, the company will be added to the S&P 500 GICS (Global Industry Classification Standard) Biotechnology Sub-Industry index.

Mariner Energy is an oil and gas exploration, development and production company operating principally in the Gulf of Mexico and the Permian Basin in West Texas. Headquartered in Houston, TX, the company will be added to the S&P MidCap 400 GICS Oil
'/>"/>

SOURCE Standard & Poor's
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Osteotechs Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio
2. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
3. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
4. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
5. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
6. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
7. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
8. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
9. Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science
10. Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy
11. WuXi AppTec VP and GM Invited to Join the AAMI Standards Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PR...aq: DCGN ) today announced the approval of all of ...rt for the District of Delaware,(the "Bankruptcy C...n for,relief under Chapter 11 of the United States... The orders issued by the Bankruptcy Court all...
(Date:11/24/2009)..., SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall...ceutical company focused on developing and commerc...d today that Anthony DiTonno, President and Chief ...21st Annual Piper Jaffray Health Care Conference, ...ce Hotel in New York, New York. ,, Mr. DiTonno...
(Date:11/24/2009)...ATTLE, Nov. 24 Blue Marble Energy ...ssa Public Development Authority (OPDA) were recen...nity Economic Revitalization Board (CERB) in a pri...irst specialty biochemical biorefinery in Lincoln ...antly speed the development of our biorefinery and...
(Date:11/24/2009)... Primary efficacy endpoint has been met for pat...rial cancer, , QUEBEC CITY, Nov. 24 /PRNewswi...ZS ; TSX: AEZ) (the "Company"), a global biopharma...oncology, today announced positive efficacy data f...ptide conjugate, AEZS-108 (formerly AN-152), in pa...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
.../Xinhua-PRNewswire-FirstCall/ --,China Biologic Pr... "the,Company"), one of the leading plasma-based p...f China ("PRC"), today announced that the Company,...Drug Administration,("SFDA") (1) to start the prod...od product prepared from plasma and (2) to commenc...
...PRNewswire/ -- Today, Tigermed,Consulting Ltd. joi...in,their CRO Service Alliance CROSA that provides ...nies. Tigermed,s expertise in clinical,development...aceutical,development capabilities of the alliance...Sciences entered into a,CRO Service Alliance in Ma...
...FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ...cused on,endocrine therapy and oncology, today ann..., Chairman and CEO of Andros Men,s Health Institut...er Presentation in a Poster,Session at the 23rd An...h,was held March 26-28, 2008 in Milan, Italy. Titl...
Other Biology Technology:China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 2China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 3Shanghai CRO Service Alliance Adds Clinical Development Capabilities 2Shanghai CRO Service Alliance Adds Clinical Development Capabilities 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6
(Date:11/24/2009)...utes fish food is a matter of debate. A high-profi...lmost 50 percent of their carbon from trees and le...errestrial and aquatic ecosystems. , But new res... is not likely to be true. Algae provide a much ri...ng to research published this week in the Proceed...
(Date:11/24/2009)... is available in Spanish . , The presence o...of inflammatory substances in the blood, hinders t...y a research project of the University of Navarra ... at the School of Pharmacy. , The project, entit...tion to the control of body weight and inflammatio...
(Date:11/23/2009)....C. The community-associated strain of the deadly...ant to most common antibioticsposes a far greater ...its way into hospitals, according to a study in th.... , The new threat is easily picked up in fitne...as increased the overall burden of MRSA within hos...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2New study finds MRSA on the rise in hospital outpatients 2Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 1Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 2Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 3Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 1Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 2Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 3Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 1Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 2Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 3
...bruary 22, 2009--Researchers at the Dana-Farber Ca...r Medical Research (Burnham) and the Centers for D...the identification of human monoclonal antibodies ...fluenza A viruses, including avian influenza A (H5...d some seasonal influenza viruses. These antibodie...
...L, N.J., Feb. 18 BIO-key International, Inc. (OTC...lease fourth quarter 2008 financial results on Tue...In conjunction with the release, BIO-key has sched...ve over the Internet on Tuesday, February 24, 2009... BIO-key International, Inc. Fourth Quarter 2...
...e quick decline of a tiny shrimp-like species, kno... aggressive population growth of non-native quagga...As invasive mussel numbers increase, food sources ...ily and unilaterally declined. , A recent researc...ratory published,this week in Freshwater Biology ...
Other Biology News:Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 2Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 3BIO-key(R) Announces Fourth Quarter and 2008 Year-End Earnings Release and Conference Call Schedule 2
...stone and M.W. Turner (1997). • This book des...production of high-quality antibodies, the use of ... antibodies and antigens, the latest ELISA techniq...assays for detecting cell-surface molecules (cell-...
Propidium Iodide (1 mg/ml). from BioVision
Vybrant Apoptosis Assay Kit #7 - Hoechst 33342/YO-PRO-1/propidium iodide - 200 assays from Molecular Probes (Invitrogen)
Rat TIMP-1 ELISA Kit from R&D Systems
Biology Products: